ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Directory Delayed

January 27, 1984

Dugan Head ACCC, Yarbro President Elects; Amos Honored

March 18, 1983

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

May 30, 2003

Another Feasibility Study For Women’s Wealth Trial? Yes And No; It’s ‘Class Of 84’s” Adieu

December 14, 1990

CALGB Chairman Schilsky To Step Down After 15 Years Leading Cooperative Group.

February 1, 2008

NIH grant success rate drops to under 20 percent after 2011 budget cuts

May 13, 2011